Summary
The c-erbB-2 protein was measured in sera of patients with breast cancer or benign breast diseases to study the significance of this protein as a tumor marker. The mean value and positive rate for this protein (assuming 20 U/ml as the cut-off value) were 11.8 U/ml (0%) in benign breast disease (n=30), 11.8 U/ml (3.1%) in stage I/II primary breast cancer (n=64), 38.2 U/ml (29.4%) in stage III/IV primary breast cancer (n=17), 17.9 U/ml (33.3%) in locally recurrent breast cancer (n=12), 298.4 U/ml (51.0%) in recurrent breast cancer with distant metastases (n=51), and 12.9 U/ml (0%) in those with no evidence of recurrence (n=57). Thus, the serum c-erbB-2 protein level was significantly higher in the distant metastatic group. In patients with distant metastases, there was a close association between expression of c-erbB-2 protein in the primary tumor and the serum c-erbB-2 protein level. On the basis of these results, serum c-erbB-2 protein was thought to be useful as a tumor marker for postoperative monitoring of breast cancer, especially in patients positive for expression of this protein in primary cancer tissue.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Akiyama T, Sudo C, Ogawara H, Toyoshima K, Yamamoto T: The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Science 232: 1644–1646, 1986
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science, 235: 177–182, 1987
Tsuda H, Hirohashi S, Shimosato Y, Tanaka Y, Hirota T, Tsugane S, Shiraishi M, Toyoshima K, Yamamoto T, Terada M, Sugimura T: Immunohistochemical study on overexpression of c-erbB-2 protein in human breast cancer: its correlation with gene amplification and long-term survival of patients. Jpn J Cancer Res 81: 327–332, 1990
Kallioniemi OP, Holli K, Visakorpi T, Koivula T, Helin HH, Isola JJ: Association of c-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer. Int J Cancer 49: 650–655, 1991
Leitzel K, Teramoto Y, Sampson E, Mauceri J, Langston BC, Demers L, Podezasky E, Harvey H, Shambough S, Volas G, Weaver S, Lipton A: Elevated soluble c-erbB-2 antigen levels in the sera and effusions of a proportion of breast cancer patients. J Clin Oncol 10: 1436–1443, 1992
Longton BC, Crenshaw MC, Chao LA, Stuart SG, Akita RW: An antigen immunologically related to the external domain of gp185 is shed from nude mouse tumors overexpressing the c-erbB-2(HER-2/neu) oncogene. Cancer Res 51: 2593–2598, 1991
Mori S, Mori Y, Mukaiyama T, Yamada Y, Sonobe Y, Matsushita H, Sakamoto G, Akiyama T, Ogawa M, Shiraishi M, Toyoshima K, Yamamoto T: In vitro andin vivo release of soluble erbB-2 protein from human carcinoma cells. Jpn J Cancer Res 81: 489–494, 1990
McKenzie SJ: Diagnostic utility of oncogenes and their products in human cancer. Biochem Biophys Acta 1072: 193–214, 1991
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Narita, T., Funahashi, H., Satoh, Y. et al. C-erbB-2 protein in the sera of breast cancer patients. Breast Cancer Res Tr 24, 97–102 (1992). https://doi.org/10.1007/BF01961242
Issue Date:
DOI: https://doi.org/10.1007/BF01961242